A mice model refers to laboratory mice that are genetically engineers or breeds to study human diseases, drug reactions and biological processes. These models are widely used in biomedical research, due to their genetic similarity for humans, small reproductive cycles and ease of handling. The model of mice market growth is inspired by increasing demand for preclinical study, increase in drug discovery and investment in cancer research, progress in genetic engineering technologies such as CRISPR and increasing attention to individual medicine. Additionally, the requirement of accurate and cost-effective models for the study of complex diseases enhances the adoption of models of innovative and humanized mice.
Key Growth Drivers and Opportunities
Rising Demand for Preclinical Studies: The growing demand for preclinical studies is significantly increasing the growth of the market model of mice, as laboratory mice are essential tools in evaluating new drugs and remedies before human tests. Pharmaceutical and biotechnology companies greatly rely on the models of mice to stimulate human diseases, test drug candidates and assess biological reactions in a controlled environment. There is a growing requirement of models of exact, reliable and genetically engineer mice, especially in oncology, neurology and genetic disorders, with R&D investment. This bounce in pregnancy research accelerates the demand for models of advanced and human-to-human mice, fuel the expansion of the market and innovation.
Challenges
The mice models face many boundaries in the market that can obstruct its growth and effectiveness. A major challenge is a biological difference between mice and humans, which can lead to incorrect predictions of human reactions to drugs or diseases, limiting the translation value of research. Additionally, moral concerns about animal testing, with strict regulatory guidelines, can restrict the experiment and increase research costs. High maintenance and reproductive costs, especially for models of genetically modified or human rats, also create financial obstacles for small research institutes. In addition, increasing availability of optional in in vitro and computational models can reduce dependence on animal models over time.
Innovation and Expansion
Researchers Created the First Completely Working Human Immune System Mouse Model
In July 2024, A biological research discovery offers fresh perspectives on disease modeling and immunotherapy development. Researchers at The University of Texas Health Science Center in San Antonio have developed a humanized mouse model that can mount certain antibody responses because it has a human immune system and a gut flora similar to that of humans. The multi-year effort, which was published in the August 2024 issue of Nature Immunology, aimed to build a humanized mouse with a fully functional human immune system in order to overcome the limits of the in vivo human models that are currently available.
The resultant humanized mice, known as TruHuX (for truly human, or THX), have a complete and functional human immune system, complete with lymph nodes, germinal centers, human T and B lymphocytes, memory B lymphocytes, thymus human epithelial cells, and plasma cells that produce highly specific antibodies and autoantibodies that are exactly like those found in humans.
The RenMice Series for Advanced Drug Discovery is Officially Launched by Biocytogen
In September 2023, The RenMice series, which consists of a set of independently created, completely human antibody mice and TCR mice with exclusive intellectual property, was formally disclosed by Biocytogen Pharmaceuticals Co., Ltd. As “human,” the term “Ren” is derived from the Chinese pinyin for “人” (rén), which incorporates Eastern cultural elements and symbolizes Biocytogen’s dedication to creating cutting-edge technologies that promote the discovery, development, and delivery of novel therapeutics, ultimately improving human health.
RenMab, RenLite, RenNano, RenTCR, and RenTCR-mimic are the five strains of completely human antibody/TCR mice that make up the RenMice line. completely human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, completely human T-cell receptors (TCRs), and TCR-mimic antibodies have all been found using these animals.
Inventive Sparks, Expanding Markets
The key players operating in the mice model market include Charles River Laboratories, (US) The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Envigo (US), JANVIER LABS (France), genOway (France), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioservices (France), Ingenious Targeting Laboratory (US), Cyagen Biosciences (US), GVK BIO (India), The Andersons, Inc. (US), Innovive (US), Allentown, LLC (US), FENGSHI Group (China), Ozgene Pty Ltd. (Australia), and Harbour Biomed (US).
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
